NCT Number: NCT00896948
Study of Proteins in Head and Neck Cancer Cells
RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.
Looking for future studies?
Notify MeKey information
Age range
Up to 120 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
About this study
OBJECTIVES:
- Define the function and mechanism of LZAP in regulating ARF.
- Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
- Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.
OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Head and neck cancer tumor cell line
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Treatment and study plan
TdT-mediated dUTP nick end labeling assay
Geneticgene expression analysis
Geneticprotein expression analysis
Geneticflow cytometry
Otherfluorescent antibody technique
Otherimmunoenzyme technique
Otherimmunohistochemistry staining method
Otherimmunologic technique
OtherPrimary outcomes
-
Function and mechanism of LZAP in regulating ARF
-
Mechanism and biological consequences of LZAP inhibition of NF-κB
-
Determination of LZAP tumor suppressor activity
Sponsors and collaborators
Lead sponsor
Vanderbilt University Medical Center
Other
Collaborators
- National Cancer Institute (NCI)
Registry information
Official study title
Novel Protein Regulator of Tumor Suppressor ARF & NF-κB
Important dates
- Study start
- 2005
- First posted
- May 12, 2009
- Registry last updated
- Mar 14, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Alcohol Cessation Among Head and Neck Cancer Survivors
NCT05570851
Alcohol Drinking, Alcohol Use, Unspecified
Manhasset, New York, United States
View Trial DetailsImplementation and Effectiveness Trial of HN-STAR
NCT04208490
Head and Neck Cancer, Head and Neck Neoplasms
Kingman, Arizona, United States
View Trial DetailsModulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
NCT03117946
Head and Neck Cancer, Head and Neck Neoplasms
Besançon, France
View Trial DetailsOSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00076310
Carcinoma, Carcinoma, Squamous Cell
Houston, Texas, United States
View Trial Details